| P50 | author | Eu-Leong Yong | Q42432836 |
| P2093 | author name string | Lei Li | |
| | Inthrani Raja Indran | |
| | Nicholas Chew | |
| | Ee Min Tan | |
| P2860 | cites work | A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. | Q38828025 |
| | Genistein inhibits osteoclastic differentiation of RAW 264.7 cells via regulation of ROS production and scavenging | Q38985154 |
| | Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells | Q39102191 |
| | Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells | Q39366263 |
| | RANKL-mediated osteoclast formation from murine RAW 264.7 cells | Q39434970 |
| | Phytoestrogens directly inhibit TNF-α-induced bone resorption in RAW264.7 cells by suppressing c-fos-induced NFATc1 expression | Q39602490 |
| | Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production | Q39654280 |
| | Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. | Q39659940 |
| | Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells | Q39740687 |
| | RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis | Q39761712 |
| | NADPH oxidase-derived reactive oxygen species are essential for differentiation of a mouse macrophage cell line (RAW264.7) into osteoclasts | Q39877127 |
| | Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens. | Q40472853 |
| | Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. | Q40562994 |
| | The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis | Q42182548 |
| | Autoamplification of NFATc1 expression determines its essential role in bone homeostasis | Q42972503 |
| | Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro | Q46279277 |
| | A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation | Q46427712 |
| | Naringenin inhibits human osteoclastogenesis and osteoclastic bone resorption | Q46427759 |
| | Impact of hip and vertebral fractures on quality-adjusted life years. | Q50760212 |
| | The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats. | Q51264121 |
| | The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. | Q51925121 |
| | Icaritin Attenuates Myocardial Ischemia and Reperfusion Injury Via Anti-Inflammatory and Anti-Oxidative Stress Effects in Rats. | Q53353117 |
| | Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. | Q53637750 |
| | Icaritin exhibits anti-inflammatory effects in the mouse peritoneal macrophages and peritonitis model. | Q54313705 |
| | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 |
| | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 | Q24537518 |
| | Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay | Q24806517 |
| | Regulation of NFATc1 in Osteoclast Differentiation | Q27021109 |
| | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| | TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 |
| | Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 |
| | TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation | Q31717820 |
| | Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1. | Q33227425 |
| | Sc65 is a novel endoplasmic reticulum protein that regulates bone mass homeostasis | Q34033354 |
| | A 3D scanning confocal imaging method measures pit volume and captures the role of Rac in osteoclast function | Q34259117 |
| | SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responses | Q34302552 |
| | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond | Q34366449 |
| | Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study | Q34404659 |
| | Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. | Q34617383 |
| | Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 |
| | Perspective. How many women have osteoporosis? | Q35437028 |
| | Discovery of small molecule CD40-TRAF6 inhibitors | Q35549406 |
| | A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein | Q35907414 |
| | A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants | Q36087132 |
| | The regulation of proteasome degradation by multi-ubiquitin chain binding proteins | Q36155975 |
| | Inhibition of Osteoclastogenesis and Bone Resorption in vitro and in vivo by a prenylflavonoid xanthohumol from hops | Q36333546 |
| | Osteoporosis: a still increasing prevalence | Q36385297 |
| | The 1-year mortality of patients treated in a hip fracture program for elders | Q36683942 |
| | TRAFs in RANK signaling | Q36882616 |
| | Adverse effects of bisphosphonates: implications for osteoporosis management | Q37246255 |
| | Sequential activation of phosphatidylinositol 3-kinase, beta Pix, Rac1, and Nox1 in growth factor-induced production of H2O2. | Q37732032 |
| | Preclinical studies and clinical evaluation of compounds from the genus Epimedium for osteoporosis and bone health. | Q38714973 |
| P433 | issue | 4 | |
| P304 | page(s) | 846-860 | |
| P577 | publication date | 2017-02-23 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | TRAF6 Mediates Suppression of Osteoclastogenesis and Prevention of Ovariectomy-Induced Bone Loss by a Novel Prenylflavonoid | |
| P478 | volume | 32 | |